Price movement over the last 24 hours
Alcon AG vs Rocket Lab USA Inc — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while Rocket Lab USA Inc trades at $84.55 (market cap $52.12B). The key difference: Rocket Lab USA Inc is the larger of the two by market cap, and Alcon AG pays a 0.54% dividend while Rocket Lab USA Inc pays none. Which is the better fit depends on your goals.
| ALC | RKLB | |
|---|---|---|
Market Cap | $32.69B | $52.12B |
Sector | Health | Technology |
52-Week High | $92.22 | $150.23 |
52-Week Low | $62.02 | $38.74 |
Enterprise Value | $36.28B | $50.87B |
Dividend Yield | 0.54% | — |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Rocket Lab (RKLB) trades at $93.09, down 7.34% amid broader market pressure on space stocks. The stock shows bearish technical signals with key support at $90 and resistance at $96. Fundamentally, the company continues to operate at a loss with a negative net income margin of -26.87% despite recent mission successes for the Space Force. The $8 billion Iridium acquisition announcement positions Rocket Lab for vertical integration but adds significant financial complexity.
Wall Street maintains a bullish stance with 75% buy ratings and a $119.10 consensus target, representing 28% upside. However, execution risks from the massive acquisition, persistent cash burn, and rich valuation at 76x sales create substantial headwinds. The stock offers growth potential in the expanding space economy but requires careful risk management given current financial metrics.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →